Literature DB >> 28110577

Preconception carrier screening and prenatal diagnosis in thalassemia and hemoglobinopathies: challenges and future perspectives.

Joanne Traeger-Synodinos1, Cornelis L Harteveld2.   

Abstract

INTRODUCTION: Hemoglobinopathies constitute the most common severe monogenic disorders worldwide, with an increasing global burden each year. The benefit of applying programmes for preconception carrier screening, with the option of prenatal diagnosis, to minimize the incidence of new cases is recognized in many countries. Areas covered: The challenges associated with identifying carrier couples using hematology-based screening, along with DNA diagnosis and prenatal diagnosis were addressed, based on a literature search and the authors expertise. Expert commentary: The hemoglobinopathies are extremely heterogeneous at the haematological, molecular and clinical level, requiring appropriately equipped and staffed laboratories with experience to support comprehensive screening and diagnosis. However complete services with adequate infrastructure to address the associated technical challenges do not exist widely, especially in low-income countries that, coincidentally, are often those with the highest frequency of hemoglobinopathies in their population. Additionally, overcoming limited public awareness, education and absence of systematic dissemination of information also constitutes a challenge. This article aims to highlight these challenges and to evaluate potential future developments that may address at least some of them, focusing mainly on the technical challenges related to molecular diagnostics.

Entities:  

Keywords:  Hemoglobinopathies; health burden; preconception carrier screening; prenatal diagnosis; sickle cell syndromes; thalassemia

Mesh:

Year:  2017        PMID: 28110577     DOI: 10.1080/14737159.2017.1285701

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  6 in total

1.  Prenatal diagnosis of thalassemia in 695 pedigrees from southeastern China: a 10-year follow-up study.

Authors:  Hailong Huang; Meihuan Chen; Lingji Chen; Min Zhang; Yan Wang; Na Lin; Liangpu Xu
Journal:  J Clin Lab Anal       Date:  2021-09-04       Impact factor: 2.352

2.  Evaluation of intervention strategy of thalassemia for couples of childbearing ages in Centre of Southern China.

Authors:  Fan Jiang; Liandong Zuo; Jian Li; Guilan Chen; Xuewei Tang; Jianying Zhou; Yanxia Qu; Dongzhi Li; Can Liao
Journal:  J Clin Lab Anal       Date:  2021-09-07       Impact factor: 2.352

Review 3.  Molecular Epidemiology and Hematologic Characterization of Thalassemia in Guangdong Province, Southern China.

Authors:  Jiajia Xian; Yanchao Wang; Jianchun He; Shaoying Li; Wenzhi He; Xiaoyan Ma; Qing Li
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 4.  The hemoglobinopathies, molecular disease mechanisms and diagnostics.

Authors:  Cornelis L Harteveld; Ahlem Achour; Sandra J G Arkesteijn; Jeanet Ter Huurne; Maaike Verschuren; Sharda Bhagwandien-Bisoen; Rianne Schaap; Linda Vijfhuizen; Hakima El Idrissi; Tamara T Koopmann
Journal:  Int J Lab Hematol       Date:  2022-09       Impact factor: 3.450

5.  Clinical utility of combined preimplantation genetic testing methods in couples at risk of passing on beta thalassemia/hemoglobin E disease: A retrospective review from a single center.

Authors:  Chonthicha Satirapod; Matchuporn Sukprasert; Bhakbhoom Panthan; Angkana Charoenyingwattana; Pawares Chitayanan; Wasun Chantratita; Wicharn Choktanasiri; Objoon Trachoo; Suradej Hongeng
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

6.  Social and cultural influences on genetic screening programme acceptability: A mixed-methods study of the views of adults, carriers, and family members living with thalassemia in the UK.

Authors:  Felicity K Boardman; Corinna Clark; Elsita Jungkurth; Philip J Young
Journal:  J Genet Couns       Date:  2020-03-01       Impact factor: 2.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.